Brit health care agency says no to earlier use of Zytiga

|By:, SA News Editor

Britain's healthcare cost effectiveness agency NICE says J&J's (JNJ) Zytiga (abiraterone) is not worth giving to patients who have yet to receive chemotherapy. The drug is currently approved for use in some men after chemo.

Apparently, J&J's own economic model shows Zytiga is not cost effective when used earlier. The once-daily tablet costs 2,930 pounds ($4,900) for a 120-tablet regimen.

Institute of Cancer Research deputy chief executive Paul Workman is disappointed in NICE's decision and urges the parties to work together on a revised price that would make the economics attractive.